THC vs UHS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: UHS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. THC and UHS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined THC and UHS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.

Full THC guide

Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. Its two core segments are acute care, which covers general hospitals and emergency and surgical services, and behavioral health, which spans inpatient psychiatric and addiction treatment facilities where UHS is one of the largest operators in the country. The company also expanded its virtual behavioral health reach through the acquisition of Talkspace.

Full UHS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.
• UHS drivers: Behavioral health scale; Acute care volumes and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. For UHS, the largest risks are tied to government reimbursement.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick THC if you believe its drivers more; UHS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the THC and UHS guides.

THC. Tenet trades at a modest earnings multiple typical of hospital operators, reflecting reimbursement and leverage risk, but the multiple has expanded from prior years as USPI mix shift, margin gains, and deleveraging improved earnings quality. The 2026 outlook calls for net operating revenue of roughly $21.5 to $22.3 billion. Figures are approximate and drawn from reported results and company guidance as of mid 2026.

UHS. UHS trades at a notably low price-to-earnings multiple, in the high single digits, well below broader market averages and its own longer-run history. That reflects investor caution around reimbursement and policy exposure rather than weak results, since revenue grew about 9.7 percent in 2025 and momentum carried into 2026.

Headline figures (approximate, mid 2026): THC shows revenue (ttm) ~$21.4 billion, fy2025 net operating revenue ~$21.3 billion (up ~3.7%), fy2025 adjusted diluted eps ~$16.78 (up ~41%), ebitda margin ~22-23%; UHS shows revenue (fy2025) ~$17.4B, net income attributable to uhs (fy2025) ~$1.49B, diluted eps (fy2025) ~$23.10, market cap ~$10B.

THC and UHS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined THC and UHS exposure against your real portfolio. It is not an investment adviser.